<DOC>
	<DOCNO>NCT01898104</DOCNO>
	<brief_summary>The purpose study first determine maximum tolerate dose capecitabine give alone combination valproic acid preoperative short-course radiotherapy ( Phase 1 ) . The next part study ( Phase 2 ) explore whether addition valproic acid addition capecitabine short-course radiotherapy , optimal radical surgery might increase pathologic complete tumor regression rate patient low-moderate risk rectal cancer .</brief_summary>
	<brief_title>Preoperative Valproic Acid Radiation Therapy Rectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>• Patients histologically confirm diagnosis adenocarcinoma rectum fall one follow category : T2N0 locate &lt; 2 cm anal verge T2N1 T3N0N1 , locate &gt; 5 cm &lt; 12 cm anal verge infiltration perirectal fat distance 1 mm mesorectal fascia ( MRF ) evaluate MRI . Age ≥18 ≤ 70 ECOG Performance Status ≤1 Effective contraception male female patient risk conception exist Signed write informed consent Any previous treatment rectal cancer Previous pelvic radiotherapy Presence metastatic disease Recurrent rectal tumor Patient Familial Adenomatosis Polyposis ( FAP ) Hereditary NonPolyposis Colorectal Cancer ( HNPCC ) History inflammatory bowel disease active disease Any concurrent malignancy except adequately treat basocellular carcinoma skin situ carcinoma cervix uterus . Patients previous malignancy without evidence disease 5 year allow enter trial . Neutrophils &lt; 2000/mm3 platelet &lt; 100.000/ mm3 haemoglobin &lt; 9 gr/dl . Creatinine level indicate renal clearance &lt; 50 ml/min GOT and/or GPT &gt; 2.5 time UNL and/or bilirubin &gt; 1.5 time uppernormal limit ( UNL ) Significant cardiovascular comorbidity ( e.g . myocardial infarction , superior vena cava [ SVC ] syndrome , patient ejection fraction &lt; 50 % ) presence cardiac disease opinion Investigator increase risk ventricular arrhythmia . History arrhythmia ( multifocal premature ventricular contraction [ PVCs ] , bigeminy , trigeminy , ventricular tachycardia , uncontrolled atrial fibrillation ) symptomatic require treatment ( CTCAE grade 3 ) asymptomatic sustain ventricular tachycardia . Patients long QTsyndrome QTc interval duration &gt; 480 msec concomitant medication drug prolong QTc ( see list appendix ) Known dihydropyrimidine dehydrogenase ( DPD ) deficiency HIV positive patient Patients take oral medication , require intravenous alimentation , prior surgical procedure affect absorption , active peptic ulcer disease . Known suspected hypersensitivity study drug . Patient prior treatment HDAC inhibitor patient receive compound HDAC inhibitorlike activity , valproic acid . Concurrent uncontrolled medical condition might contraindicate study drug . Major surgical procedure , within 28 day prior study treatment start . Pregnant lactating woman . Women childbearing potential either positive pregnancy test baseline ( NB . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Sexually active male female ( childbearing potential ) unwilling practice contraception study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>rectal</keyword>
	<keyword>low risk</keyword>
	<keyword>moderate risk</keyword>
</DOC>